B.Sc. (Hons) 2:1 Immunology, University of Edinburgh 1994
Ph.D. Virology University of Glasgow 2002
Post-Doctoral Researcher, 2002-2005 Children's National Medical Center, Washington D.C., USA.
Invesigator Scientist 2005-2007 MRC-5 Virology Unit, Glasgow
1994-1998 Clinical Research Manager, The Procter & Gamble Company, London UK. Managed clinical trials in Europe, North American and China. Included 6 month secondment to Health Care Research Center, Cincinnati, Ohio, USA..
2007 -2016 Virology Manager, SGS Vitrology Ltd., Glasgow, UK.
2016 - Present Virology and Technical Support Manager, SGS Vitrology Ltd., Glasgow UK.
Dr. Richard Adair obtained his Honours degree in Immunology in 1994 from the University of Edinburgh. For the following four years he worked as a Clinical Research Manager for Procter & Gamble Technical Centres Ltd. based in Staines, but undertook management of clinical research trials in numerous international locations, including the USA and the Peoples Republic of China. As part of Richard’s training he was based at the healthcare R&D world headquarters in Cincinatti, Ohio, for six months in 1997. Richard returned to academia in 1998 to undertake a PhD in Virology at the MRC Virology Unit in Glasgow, studying the US22 gene family of human cytomegalovirus (HCMV). In March 2002, Richard undertook an NIH funded post-doctoral position at Children’s National Medical Center, Washington, DC, studying regulation of gene splicing of the UL37 gene of HCMV. In 2005 Richard returned to the UK to undertake a position as an Investigator Scientist in the MRC Virology Unit, working on hepatitis C gene regulation. In 2007 Richard joined Vitrology Limited (becoming SGS Vitrology Limited in 2012) as the Virology Manager. In 2016 he expanded his role to Virology Manager and Virology Technical Support Manager, with roles in both operations and business support.
Honors & Awards
Taylor R.R., Egan A., McGuinness D., Jepson A., Adair R., Drakely C. and Riley E. 1996 "Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting." International Immunology 8(6):905-915
Owens J., Addy M., Faulkner J., Lockwood C., Adair R. 1997 "A short-term clinical study design to investigate the chemical plaque inhibitory properties of mouthrinses when used as adjuncts to toothpastes: applied to chlorhexidine" Journal of Clinical Periodontology 24:732-737
Scully C., El-Kabir M., Greenman J., Porter S.R., Mutlu S., Barton I. and Adair R. 1999 "The effects of mouth rinses and dentifrice containing magnesium monoperoxyphthalate (mmpp) on oral microflora, plaque reduction, and mucosa." Journal of Clinical Periodontology 26(4):234-238
Levinkind M., Owens J., Morea C., Addy M., Lang N.P., Adair R. and Barton I. 1999 "The development and validation of an occlusal site-specific plaque index to evaluate the effects of cleaning by tooth brushes and chewing gum." Journal of Clinical Periodontology 26(3):177-182
Adair R., Douglas E.R., Maclean J.B., Graham S.Y., Aitken J.D., Jamieson F.E. and Dargan D.J. 2002 “The products of human cytomegalovirus genes UL23, UL24, UL43 and US22 are tegument components.” Journal of General Virology 83: 1315-1324
Su Y., Testaverde J.R., Davis C.N., Hayajneh W.A., Adair R., and Colberg-Poley A.M. 2003. Human cytomegalovirus UL37 immediate early target minigene RNAs are accurately spliced and polyadenylated. Journal of General Virology 84:29-39.
Adair R., Liebisch G.W. and Colberg-Poley A.M. 2003. Complex alternative processing of human cytomegalovirus (HCMV) UL37 pre-mRNA. Journal of General Virology 84:3353-3358
Su Y., Adair R., Davis C.N., DiFronzo N.L., and Colberg-Poley A.M. 2003. Convergence of RNA cis-elements and cellular polyadenylation factors in the regulation of human cytomegalovirus UL37 exon 1 unspliced RNA production. Journal of Virology 77:12729-12741
Adair R., Liebisch G.W., Su Y., and Colberg-Poley A.M. 2004. Alteration of cellular RNA splicing and polyadenylation machineries during productive human cytomegalovirus infection. Journal of General Virology 85:3541-3553
Adair R., Liebisch G.W., Lerman B.J. and Colberg-Poley A.M. 2006. Human cytomegalovirus temporally regulated gene expression in differentiated, immortalized retinal pigment epithelial cells. Journal of Clinical Virology 35:478-484. First published online December 2005
Berro R., Kehn K., Fuente C., Pumfery A., Adair R., Wade J., Colberg-Poley A.M., Hiscott J., and Kashanchi F. 2006. Acetylated Tat regulates human immunodeficiency virus type 1 splicing through its interaction with the splicing regulator p32. Journal of Virology 80(7): 3189-3204
Perotti M, Mancini N, Diotti R.A., Tarr A.W., Ball J.K., Owisanka A., Adair R., Patel A.H., Clementi M. and Burioni R. Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the Hepatitis C virus E2 protein. J Virol. 2008 Jan;82(2):1047-1052.
Owsianka A.M., Tarr A.W., Keck Z-Y., Li T-K., Witteveldt J., Adair R., Foung S.K.H., Ball J.K. and Patel A.H. 2008. Broadly neutralizing human monoclonal antibodies to the hepatitis c virus E2 glycoprotein. Journal of General Virology 89: 653-659
Adair R., Patel A.H., Corless L., Griffin S., Rowlands D.J. and McCormick C.J. 2009. Expression of hepatitis C virus (HCV) structural proteins in trans facilitates encapsidation and transmission of HCV subgenomic RNA. Journal of General Virology90: 833-842
Angus A.G.N., Dalrymple D., Boulant S., McGivern D.R., Clayton R.F., Scott M.J., Adair R., Graham S., Owsianka A.M., Targett-Adams P., Li K., Wakita T., McLauchlan J., Lemon S.M. and Patel A.H. 2010. Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein. Journal of General Virology 92: 122-132
Brown K.S., Keogh M.J., Owianka A.M., Adair R., Patel A.H., Arnold J.N., Ball J.K., Sim R.B., Tarr A.W. and Hickling T.P. 2010. Specific interaction of hepatitis C glycoproteins with mannan binding lectin inhibits virus entry. Protein & Cell 1(7): 664-674
Control Viral Contaminants with Effective Testing. 2017. BioPharm International Volume 30(10): 18.
Considerations for biosafety testing of cell and gene therapies
Regulatory authorities such as the US Food & Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA) impose stringent limits on the amount of microbial contaminates and impurities present during the manufacturing of biological medicines and vaccines, and present in cell and gene therapy products. These regulations ensure sterile products and thus patient safety. To establish that the testing procedures are accurate, regulatory authorities require proof of testing before clinical trials can be approved or a batch of commercial biopharmaceuticals or vaccines be released. Consequently, all components of the manufacturing process must undergo extensive safety testing to demonstrate identity, stability, and purity. This talk will review general approaches to biosafety testing, with specific focus related to cell and gene therapies.